Volume 26, Number 7—July 2020
Research
Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease Patients
Table 1
Cohort |
Country |
Sample source |
Infection |
No. samples |
Postdiagnosis range or time |
---|---|---|---|---|---|
A | The Netherlands | Healthy blood donors (negative cohort) | NA | 45 | NA |
B |
The Netherlands |
Non-CoV respiratory infections† |
Adenovirus | 5 | 2–4 wk |
Bocavirus | 2 | 2–4 wk | |||
Enterovirus | 2 | 2–4 wk | |||
HMPV | 9 | 2–4 wk | |||
Influenza A | 13 | 2–4 wk | |||
Influenza B | 6 | 2–4 wk | |||
Rhinovirus | 9 | 2–4 wk | |||
RSV | 9 | 2–4 wk | |||
PIV-1 | 4 | 2–4 wk | |||
PIV-3 | 4 | 2–4 wk | |||
Mycoplasma pneumoniae | 1 | 2–4 wk | |||
CMV | 5 | 2–4 wk | |||
EBV |
7 |
2–4 wk |
|||
C |
The Netherlands |
HCoV infections† |
α-CoV HCoV-229E | 19 | 2 w–1 y |
α-CoV HCoV-NL63 | 18 | 2 w–1 y | |||
β-CoV HCoV-OC43 |
38 |
2 w–1 y |
|||
D |
The Netherlands | Zoonotic CoV infections† | MERS-CoV |
2 | 10,228 d |
South Korea |
5 |
9 mo |
|||
E |
Hong Kong, China |
Zoonotic CoV infection† |
SARS-CoV |
2 |
>14 d |
F | France | RT-PCR confirmed SARS-CoV-2 infections | Mild infection | 6‡ | 3–27 d |
Severe infection | 4§ | 6–31 d |
*Cohorts A–E were used to test assay specificity; cohort F was used to test assay sensitivity. α-CoV, alphacoronavirus; β-CoV, betacoronavirus; CoV, coronavirus; CMV, cytomegalovirus; EBV, Epstein-Barr virus; HCoV, human coronavirus; HMPV, human metapneumovirus; MERS, Middle East respiratory syndrome; NA, not applicable; PIV, parainfluenza virus; RSV, respiratory syncytial virus; RT-PCR, reverse transcription PCR.
†Cross-reactivity.
‡Samples taken from 2 patients at different time points.
§Samples taken from 1 patient at different time points.
1These authors contributed equally to this article.
Page created: April 08, 2020
Page updated: June 18, 2020
Page reviewed: June 18, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.